RU2769694C2 - C5-Анилинохиназолиновые соединения и их использование в лечении рака - Google Patents

C5-Анилинохиназолиновые соединения и их использование в лечении рака Download PDF

Info

Publication number
RU2769694C2
RU2769694C2 RU2019136279A RU2019136279A RU2769694C2 RU 2769694 C2 RU2769694 C2 RU 2769694C2 RU 2019136279 A RU2019136279 A RU 2019136279A RU 2019136279 A RU2019136279 A RU 2019136279A RU 2769694 C2 RU2769694 C2 RU 2769694C2
Authority
RU
Russia
Prior art keywords
compound
triazol
amino
acetamide
phenyl
Prior art date
Application number
RU2019136279A
Other languages
English (en)
Russian (ru)
Other versions
RU2019136279A (ru
RU2019136279A3 (enExample
Inventor
Тюдор ГРЕКУ
Джейсон Грант Кеттл
Мартин Джон ПАКЕР
Стюарт Эрик ПИРСОН
Джеймс Майкл Смит
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2019136279A publication Critical patent/RU2019136279A/ru
Publication of RU2019136279A3 publication Critical patent/RU2019136279A3/ru
Application granted granted Critical
Publication of RU2769694C2 publication Critical patent/RU2769694C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2019136279A 2017-04-27 2018-04-26 C5-Анилинохиназолиновые соединения и их использование в лечении рака RU2769694C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490859P 2017-04-27 2017-04-27
US62/490,859 2017-04-27
PCT/EP2018/060798 WO2018197642A1 (en) 2017-04-27 2018-04-26 C5-anilinoquinazoline compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
RU2019136279A RU2019136279A (ru) 2021-05-27
RU2019136279A3 RU2019136279A3 (enExample) 2021-05-31
RU2769694C2 true RU2769694C2 (ru) 2022-04-05

Family

ID=62091877

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019136279A RU2769694C2 (ru) 2017-04-27 2018-04-26 C5-Анилинохиназолиновые соединения и их использование в лечении рака

Country Status (13)

Country Link
US (2) US10273227B2 (enExample)
EP (1) EP3615522B1 (enExample)
JP (1) JP7128204B2 (enExample)
KR (1) KR102603153B1 (enExample)
CN (1) CN110573505B (enExample)
AR (1) AR111494A1 (enExample)
AU (1) AU2018259078B2 (enExample)
CA (1) CA3059283A1 (enExample)
ES (1) ES2888298T3 (enExample)
MX (1) MX389244B (enExample)
RU (1) RU2769694C2 (enExample)
TW (1) TWI774758B (enExample)
WO (1) WO2018197642A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
US20240034788A1 (en) * 2020-08-20 2024-02-01 The Board Of Trustees Of The Leland Stanford Junior University Abscopal therapy for cancer
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
KR20230064560A (ko) * 2021-10-29 2023-05-10 보로노이바이오 주식회사 퀴나졸린 유도체 화합물 및 이의 용도
MX2024007044A (es) * 2021-12-09 2024-09-04 Deciphera Pharmaceuticals Llc Compuestos heterociclicos como inhibidores de kit quinasa.
US20250275978A1 (en) * 2024-03-04 2025-09-04 Cardiff Oncology, Inc. Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178382A1 (en) * 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
RU2434010C2 (ru) * 2007-06-05 2011-11-20 Ханми Фарм. Ко., Лтд. Новое амидное производное для ингибирования роста раковых клеток

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20070106549A1 (en) 2005-11-04 2007-05-10 Stocking Christine A Turnkey aviation budget management
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2009140549A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN103254142B (zh) 2013-04-26 2015-10-28 浙江工业大学 4-[4-(2-取代氨基乙酰氨基)苯胺基]喹唑啉类衍生物及制备和应用
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104130200B (zh) 2014-07-01 2016-04-20 中山大学 一种2-取代苯基-4-芳胺基喹唑啉衍生物及其制备方法和应用
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US11053223B2 (en) 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709479B1 (en) * 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
US20060178382A1 (en) * 2003-06-17 2006-08-10 Astrazeneca Ab Chinazoline derivatives as aurora kinase inhibitors
RU2434010C2 (ru) * 2007-06-05 2011-11-20 Ханми Фарм. Ко., Лтд. Новое амидное производное для ингибирования роста раковых клеток

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rao, G.-W. и др.: Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors, ChemMedChem, 2013, 8(6), с.928-933. *

Also Published As

Publication number Publication date
US20190263787A1 (en) 2019-08-29
US20180312490A1 (en) 2018-11-01
MX389244B (es) 2025-03-20
EP3615522B1 (en) 2021-08-04
JP2020517677A (ja) 2020-06-18
AU2018259078A1 (en) 2019-10-17
KR102603153B1 (ko) 2023-11-15
KR20190141203A (ko) 2019-12-23
JP7128204B2 (ja) 2022-08-30
AU2018259078B2 (en) 2021-10-07
BR112019022229A2 (pt) 2020-05-12
US10273227B2 (en) 2019-04-30
RU2019136279A (ru) 2021-05-27
TW201904960A (zh) 2019-02-01
CN110573505A (zh) 2019-12-13
EP3615522A1 (en) 2020-03-04
RU2019136279A3 (enExample) 2021-05-31
ES2888298T3 (es) 2022-01-03
MX2019012847A (es) 2022-01-07
CA3059283A1 (en) 2018-11-01
US10829479B2 (en) 2020-11-10
TWI774758B (zh) 2022-08-21
WO2018197642A1 (en) 2018-11-01
CN110573505B (zh) 2023-04-11
AR111494A1 (es) 2019-07-17

Similar Documents

Publication Publication Date Title
KR102603153B1 (ko) C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도
RU2656597C2 (ru) Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
JP6538830B2 (ja) １，３，４−チアジアゾール化合物および癌を治療する際のその使用
TW201703768A (zh) 苯胺嘧啶衍生物及其用途
EP3615526B1 (en) Phenoxyquinazoline compounds and their use in treating cancer
KR20220122597A (ko) 약학적 화합물
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
BR112019022229B1 (pt) Compostos de anilinoquinazolina c5, composição farmacêutica e uso dos compostos no tratamento do câncer
JP2025526715A (ja) ピリジノピリミジノン化合物の結晶、その酸塩、その酸塩の結晶及び使用
WO2024255845A1 (zh) 一类蛋白降解剂及其药物组合物和用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
CN113493436A (zh) 胺基取代吡啶衍生物及其制法和药物组合物与用途